Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072137 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00072137: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00072137 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00072137, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of vaccine therapy given directly into the bladder in treating patients who are undergoing surgery to remove all or part of the bladder. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Giving a vaccine directly into the bladder before surgery may cause a stronger immune response and keep tumor cells from coming back after surgery.
Interventions
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Therapeutic Conventional Surgery
- OTHER Pharmacological Study
- BIOLOGICAL Recombinant Fowlpox-TRICOM Vaccine
- BIOLOGICAL Recombinant Fowlpox GM-CSF Vaccine Adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2003-10 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00072137
The ClinicalTrials.gov registry entry for NCT00072137 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00072137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00072137 about?
NCT00072137 is a clinical study titled "Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy". This phase I trial studies the side effects and best dose of vaccine therapy given directly into the bladder in treating patients who are undergoing surgery to remove all or part of the bladder. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tum...
What is the current status of trial NCT00072137?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2003-10. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00072137?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Therapeutic Conventional Surgery (PROCEDURE), Pharmacological Study (OTHER), Recombinant Fowlpox-TRICOM Vaccine (BIOLOGICAL), Recombinant Fowlpox GM-CSF Vaccine Adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT00072137?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.